More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of CX11 for obesity.

Neuren has confirmed the primary goals for its double-blind, single Phase III pivotal trial of NNZ-2591 in treating PMS for 13 weeks.

A study by Larsen and colleagues has exemplified the role that HCs have in heightening depression risk in this group.